Takahiro Shimoyama ¹, Takayuki Yamamoto ², Satoru Umegae ¹, Koichi Matsumoto ¹ , BMC Gastroenterol. 2018 Aug 1;18(1):120.

Our findings indicate that FC is a relevant biomarker, which is convenient to measure for assessing endoscopic activity and predicting relapse in patients who achieve remission following a course of GMA therapy.

https://pubmed.ncbi.nlm.nih.gov/30068300/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090982/pdf/12876_2018_Article_853.pdf

Takuro Kanekura ¹, J Dermatol 2018 Aug;45(8):943-950

These actions render GMA a unique non-pharmacological treatment option for patients with chronic dermatoid conditions, which are difficult to treat with pharmacological preparations.

https://pubmed.ncbi.nlm.nih.gov/29782055/

Osamu Nomura ¹, Taro Osada ¹, Tomoyoshi Shibuya ¹, Dai Ishikawa ¹, Keiichi Haga ¹, Tomohiro Kodani ¹, Naoto Sakamoto ¹, Tatsuo Ogihara ¹, Ken Yamaji ², Sumio Watanabe ¹ , J Clin Apher 2018 Feb;33(1):21-28.

In this retrospective efficacy evaluation, cytapheresis was effective as remission induction therapy with steroid sparing effect and desirable safety profile. Further, patients with EN or PG responded favorably to cytapheresis.

https://pubmed.ncbi.nlm.nih.gov/28581039/

Hiroki Tanaka, Satoshi Motoya, Tomoyoshi Shibuya, Satoshi Tanida, Seiichiro Kokuma, Eiji Hosoi Gastroenterology 2018 154 (6) Suppl.S-996–S-997

Background: There are few studies on the usefulness of granulocyte and monocyte adsorptive apheresis (GMA) in elderly patients with inflammatory bowel disease (IBD). We investigated the safety and effectiveness of GMA in elderly patients who participated in the Post-marketing Surveillance Study of GMA Using Adacolumn® for Patients with Inflammatory Bowel Disease Who Have Special Situations (PARTICULAR). Methods: The PARTICULAR study is a retrospective, multicenter cohort study that included patients with ulcerative colitis (UC) or Crohn’s disease (CD) who received GMA between November 2013 and March 2017. Patients with at least one special situation, including elderly patients, patients with anemia, and patients undergoing concomitant treatment with multiple immunosuppressants (IMs) were enrolled. Patients aged # 64 years were excluded from this study. GMA was performed using Adacolumn® (JIMRO, Takasaki, Japan). Each patient received up to a maximum of 11 GMA sessions. The safety of GMA was assessed in all patients. The effectiveness of GMA was assessed in patients with UC with a partial UC disease activity index (pUC-DAI) score of $ 3. Remission was defined as a pUC-DAI score of # 2. Patients receiving concomitant treatment with infliximab, adalimumab, or calcineurin inhibitors were excluded from the effectiveness assessment. The incidence of adverse events (AEs) and remission rates were compared between elderly patients with and without any special situation using univariate and multivariate logistic regression analysis. Results: A total of 125 elderly patients (118 UC, 7 CD) from 93 institutions were included. The median age was 73.2 years. Fifty-six patients did not have any special situation, and 69 had at least one or more special situations. The incidence of AEs was 11.2% in all patients. The incidence of AEs was significantly lower in elderly patients without any special situation (3.6%) than in those with at least one or more special situations (17.4%) (Figure 1A). AEs significantly occurred in elderly patients with anemia (21.9%) and on multiple concomitant IMs (23.8%) compared to those without any special situation (3.6%). Anemia and multiple concomitant IMs were identified as independent predictors for a higher incidence of AEs (Table 1). The effectiveness of GMA was assessed in 92 patients with UC. The remission rate was 48.9%. No difference was observed in the remission rate between elderly patients without any special situation (52.2%) and those with at least one or more special situations (45.7%) (Figure 1B). Conclusions: A low incidence of AEs (3.6%) was found in elderly IBD patients receiving GMA without any special situation. Remission was achieved by GMA in 48.6% of the elderly UC patients. Care should be taken when using GMA in elderly IBD patients with anemia or on multiple concomitant IMs

Helena Rolandsdotter ^1 2, Michael Eberhardson ^1 3, Ulrika L Fagerberg ^4 5, Yigael Finkel ^1 2 , J Pediatr Gastroenterol Nutr 2018 Jan;66(1):84-89.

Objective: The aim of the study was to analyze the effect of granulocyte and monocyte apheresis (GMA) with mesalazine for induction of remission in pediatric patients with newly onset chronic inflammatory bowel disease (IBD) colitis. Methods: Thirteen pediatric patients with newly onset extensive IBD colitis were investigated per the ECCO/ESPGHAN IBD protocol. Of these 13, 12 received 10 treatments with Adacolumn (ADA) during a median of 6.25 weeks in combination with low-to-moderate doses of mesalazine, which was continued after apheresis. A control colonoscopy was performed 12 to 16 weeks after GMA treatment. Primary outcomes were mucosal healing (Mayo endoscopic score) and histopathologic grading of biopsies. A secondary outcome was disease activity as measured by the Pediatric Ulcerative Colitis Activity Index. Results: Twelve children (6 girls) with a median age of 14.6 years and a median duration of symptoms at diagnosis of 3.2 months received all planned 10 treatment sessions with ADA. Ten of 12 patients had pancolitis and 2 of 12 extensive colitis. A final diagnosis, however, indicated ulcerative colitis in 10 children and Crohn disease in 2 children. At control colonoscopy, 8 of 12 children were in clinical remission and the Mayo endoscopic score showed significant improvement in 9 of 12 patients (P = 0.006). Complete microscopic remission, according to the Geboes score, was observed in 2 patients. Conclusions: In this small study GMA for induction of remission of newly onset pediatric IBD colitis was effective in 8 of 12 patients. Further controlled studies are warranted to confirm the efficacy of this treatment model.

https://pubmed.ncbi.nlm.nih.gov/28604509/

Hidenori Ohnishi ¹, Tomonori Kadowaki ¹, Yoko Mizutani ², Emi Nishida ³, Rie Tobita ⁴, Namiko Abe ⁴, Yukie Yamaguchi ⁵, Hikaru Eto ⁶, Masaru Honma ⁷, Takuro Kanekura ⁸, Yukari Okubo ⁴, Mariko Seishima ², Toshiyuki Fukao ¹, Shigaku Ikeda ⁹ , Eur J Dermatol. 2018 Feb 1;28(1):108-111.

https://pubmed.ncbi.nlm.nih.gov/29380726/

Atsuko Matsuoka ¹, Yuko Higashi ¹, Takuro Kanekura ¹ , J Dermatol 2018 Nov;45(11):e324-e325

The combined efficacy of adalimumab with GMA on UC patients can improve the clinical curative efficacy, effectively reduce the inflammatory factors, which is beneficial to the repair of intestinal mucosal barrier function, and worthy of clinical application.

https://pubmed.ncbi.nlm.nih.gov/29740866/

Axel Dignass ¹, Ayesha Akbar ², Daniel C Baumgart ³, Gilles Bommelaer ⁴, Guillaume Bouguen ⁵, Guillaume Cadiot ⁶, Anton Gillessen ⁷, Jean-Charles Grimaud ⁸, Ailsa Hart ², Syed Hoque ⁹, Richard Makins ¹⁰, Christophe Michiels ¹¹, Jacques Moreau ¹², Purushothaman Premchand ¹³, Wolfgang Ramlow ¹⁴, Stefan Schanz ¹⁵, Sreedhar Subramanian ¹⁶, Christian von Tirpitz ¹⁷, Bruno Bonaz ¹⁸ , Scand J Gastroenterol. 2018 Apr;53(4):442-448.

This study confirms findings of the 12-week interim analysis and demonstrates that GMA apheresis provides a safe and beneficial long-term outcome for patients with chronic active UC resistant/intolerant to IS and/or TNF inhibitors.

https://pubmed.ncbi.nlm.nih.gov/29513111/

Satoshi Tanida ¹, Tsutomu Mizoshita ¹, Keiji Ozeki ¹, Takahito Katano ¹, Mamoru Tanaka ¹, Hirotada Nishie ¹, Takaya Shimura ¹, Yasuyuki Okamoto ¹, Eiji Kubota ¹, Hiromi Kataoka ¹, Takashi Joh ¹ , Ther Apher Dial. 2018 Jun;22(3):295-300.

Thus, combination therapy with intensive granulocyte and monocyte absorptive apheresis plus ustekinumab appeared to represent a safe and effective intervention for inducing clinical remission.

https://pubmed.ncbi.nlm.nih.gov/29790276/

Aya Iwasaki ¹, Hiroshi Kawakami ¹, Yukari Okubo ¹ , Ther Apher Dial. 2018 Aug;22(4):414-416.

https://pubmed.ncbi.nlm.nih.gov/29318775/